While emerging evidence, including preclinical studies, early-phase trials, and limited clinical series, suggests that KD may help overcome treatment resistance by suppressing the PI3K/Akt/mTOR pathway, reducing insulin-like growth factor-1 (IGF-1) signaling, and enhancing cancer cell susceptibility to chemotherapy and targeted therapies, robust data from large, randomized controlled trials (RCTs) remain sparse
Neuroscience 164, 9981008.10.1016/j.neuroscience.2009.09.015 20 BlmlS.WisnowskiJ
Beta-glucan-CRM197 conjugates as candidates antifungal vaccines
For CNS-targeted research specifically, topical delivery remains largely impractical because the compound must still reach the brain after crossing the skina double barrier problem
Abcam), connexin 43 (1:1,000